Bio Pharma Dive
JANUARY 24, 2024
An 11-year-old boy born deaf can hear after receiving Lilly's genetic medicine. Others, including biotechs in China and Regeneron in the U.S., are taking aim at the same drug target.
Pharmaceutical Technology
JANUARY 24, 2024
Accent Therapeutics has raised $75m in a Series C financing round to progress the development of precision cancer therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 24, 2024
According to Greek mythology, Zeus punished Prometheus for giving fire to humans. He chained Prometheus up and set an eagle to feast on his liver. Each night, the liver grew back and each day, the eagle returned for his feast. In reality, can a liver really grow back?
Pharmaceutical Technology
JANUARY 24, 2024
The company could be in line for a priority review voucher if 4D-710, currently in Phase I/II clinical trials, is approved.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JANUARY 24, 2024
The sector’s first IPO of 2024 could be positive signal for the handful of other companies that have recently laid out plans for initial public offerings.
Worldwide Clinical Trials
JANUARY 24, 2024
Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. Many of the rare disease studies we support at Worldwide have a genetic etiology, and we discuss genetics and genetic testing with these sponsors.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Rethinking Clinical Trials
JANUARY 24, 2024
In this Friday's PCT Grand Rounds, Suresh Balu and Marc Sendak of Duke University will present "Advancing the Safe, Effective, and Equitable Use of AI in Healthcare." The Grand Rounds session will be held on Friday, January 26, 2024, at 1:00 pm eastern. Balu is the director of the Duke Institute for Health Innovation (DIHI) and the associate dean for innovation and partnership in the Duke University School of Medicine.
Bio Pharma Dive
JANUARY 24, 2024
The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight-loss drugs.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 24, 2024
Challenges in the healthcare industry can be offset if the government takes several measures including land allotments for hospitals and introduce financial incentives and subsidies to healthcare providers to stimulate investments in infrastructure, medical technology, and workforce development, said Pritika Singh, CEO, Prayag Hospitals Group.
pharmaphorum
JANUARY 24, 2024
CG Oncology completes the first biotech IPO of 2024, raising $380 million for its oncolytic virus bladder cancer immunotherapy.
Pharmaceutical Technology
JANUARY 24, 2024
Amid increased restrictions on contraceptive care, HHS released plans pushing for full access to all FDA-approved contraceptives.
pharmaphorum
JANUARY 24, 2024
"The Omni Advantage: Accelerating the Behavioural Change with Omnichannel in Pharma Sales Engagement" is a game-changing book by businesswoman Merhnaz Campbell. Discover insights, strategies, and inspiration for pharma sales field team success.
Pharmaceutical Technology
JANUARY 24, 2024
Pfizer will charge $1,400 per five-day course of Paxlovid when the drug moves over to commercial sales.
Fierce Pharma
JANUARY 24, 2024
The FDA’s letter demanding a labeling change for Gilead Sciences’ Tecartus temporarily went missing on the agency’s website Tuesday. | The FDA’s letter demanding a labeling change for Gilead Sciences’ Tecartus temporarily went missing on the agency’s website Tuesday. Turns out, the FDA didn’t drop the CD19 CAR-T from a classwide safety alert list. Instead, it's adjusted the wording of a proposed boxed warning.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JANUARY 24, 2024
Bristol Myers Squibb (BMS) has concluded the acquisition of Mirati Therapeutics for $5.8bn, a move that bolsters its oncology portfolio.
Pharma Times
JANUARY 24, 2024
Patients living with sickle cell disease and thalassaemia will be eligible for the test
Pharmaceutical Technology
JANUARY 24, 2024
EraCal Therapeutics and Novo Nordisk partner on the development and marketing of an oral, small molecule programme for obesity treatment.
pharmaphorum
JANUARY 24, 2024
Is the upcoming year set to be a year of major expansion, acquisitions, and deal-making in the business world? Stay informed about the potential trends and opportunities that await in the M&A landscape.
Pharmaceutical Technology
JANUARY 24, 2024
NAYA’s acquisition includes Florida Biotechnologies’ AAV gene therapy for the treatment of a rare genetic disorder.
Pharma Times
JANUARY 24, 2024
The new company will develop novel therapies to benefit the body’s immune system
pharmaphorum
JANUARY 24, 2024
LEO Pharma's chronic hand eczema drug delgocitinib has outperformed the only approved drug for the condition in a phase 3 trial.
Outsourcing Pharma
JANUARY 24, 2024
Medable says its mission is to get effective therapies to patients faster.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JANUARY 24, 2024
BARDA has given $24 million to Locus Bio to support a mid-stage trial of bacteriophage therapy LBP-EC01 for resistant E coli infections.
Pharmaceutical Technology
JANUARY 24, 2024
AUR-105 is under clinical development by Aurigene Oncology and currently in Phase I for Leukemia.
pharmaphorum
JANUARY 24, 2024
BenevolentAI’s search for a new chief executive has concluded with the appointment of industry bigwig Dr Jörg Möller to the role, four months after Joanna Shields stepped down and as the company emerges from a restructuring drive. The UK artificial intelligence specialist said in a statement that Möller is “an accomplished R&D leader and champion of the application of AI to drug discovery.
Pharmaceutical Technology
JANUARY 24, 2024
PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
JANUARY 24, 2024
It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgoci | It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgocitinib to treat atopic dermatitis. Slowly but surely, Denmark’s Leo Pharma—which gained the rights to develop and commercialize delgocitinib in the rest of the world a decade ago—is working toward its first green light for the topical cream.
Pharmaceutical Technology
JANUARY 24, 2024
Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).
XTalks
JANUARY 24, 2024
Steakholder Foods marks a pivotal moment in the seafood industry with its latest innovation: 3D printed fish in the form of plant-based shrimp. This breakthrough, developed by a leader in cultivated meat and 3D bioprinting technology, is set to transform the $60 billion shrimp market. The company’s use of cutting-edge technology not only showcases a technological triumph but also positions it as a major disruptor in the seafood sector.
Pharmaceutical Technology
JANUARY 24, 2024
Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
305 
Let's personalize your content